Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher BioSpacePartner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner's National Priority Voucher to accelerate drug review.OncologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) BioSpace Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to accelerate drug review. Oncology Read full story Post navigation Previous: Deal finally unlocks NHS access to ITF’s Duchenne drugNext: Novo Nordisk microRNA drug fluffs its lines in heart failure Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
